Alice S. Chen-Plotkin

Alice S. Chen-Plotkin

Auto-generated profile, based on publicly available information

Alice S. Chen-Plotkin

University of Pennsylvania

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
MGMichael D. Gallagher
Michael D. Gallagher
ACAlice S. Chen-Plotkin
Alice S. Chen-Plotkin

15 August 2012 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
ACAlice S. Chen-Plotkin
Alice S. Chen-Plotkin
TUTravis L. Unger
Travis L. Unger
MGMichael D. Gallagher
Michael D. Gallagher
EBEmily Bill
Emily Bill
LKLinda K. Kwong
Linda K. Kwong
VLVirginia M.-Y. Lee
Virginia M.-Y. Lee
Frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) is a fatal neurodegenerative disease with no available treatments. Mutations in the progranulin gene (GRN) causing impaired production or secretion of progranulin are a common Mendelian cause of FTLD-TDP; additionally, common variants at chromosome 7p21 in the uncharacterized geneTMEM106Bwere recently linked by genome-wide association to FTLD-TDP with and withoutGRNmutations. Here we show thatTMEM106Bis neuronally expressed in postmortem human brain tissue, and that expression levels are increased in FTLD-TDP brain. Furthermore, using an unbiased, microarray-based screen of >800 microRNAs (miRs), we identify microRNA-132 as the top microRNA differentiating FTLD-TDP and control brains, with <50% normal expression levels of three members of the microRNA-132 cluster (microRNA-132, microRNA-132*, and microRNA-212) in disease. Computational analyses, corroborated empirically, demonstrate that the top mRNA target of both microRNA-132 and microRNA-212 isTMEM106B; both microRNAs repress TMEM106B expression through shared microRNA-132/212 binding sites in theTMEM106B3′UTR. Increasing TMEM106B expression to model disease results in enlargement and poor acidification of endo-lysosomes, as well as impairment of mannose-6-phosphate-receptor trafficking. Finally, endogenous neuronal TMEM106B colocalizes with progranulin in late endo-lysosomes, and TMEM106B overexpression increases intracellular levels of progranulin. Thus,TMEM106Bis an FTLD-TDP risk gene, with microRNA-132/212 depression as an event which can lead to aberrant overexpression of TMEM106B, which in turn alters progranulin pathways. Evidence for this pathogenic cascade includes the striking convergence of two independent, genomic-scale screens on a microRNA:mRNA regulatory pair. Our findings open novel directions for elucidating miR-based therapies in FTLD-TDP.

4 September 2021 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
WAWhitley W. Aamodt
Whitley W. Aamodt
TWTeresa Waligorska
Teresa Waligorska
JSJunchao Shen
Junchao Shen
TTThomas Tropea
Thomas Tropea
ASAndrew Siderowf
Andrew Siderowf
ACAlice S. Chen‐Plotkin
Alice S. Chen‐Plotkin

19 August 2022 in Science
Verified
Journal Article
Closed access
MDMaria E. Diaz-Ortiz
Maria E. Diaz-Ortiz
YSYunji Seo
Yunji Seo
MPMarijan Posavi
Marijan Posavi
MCMarc Carceles Cordon
Marc Carceles Cordon
ECElisia Clark
Elisia Clark
ACAlice S. Chen-Plotkin
Alice S. Chen-Plotkin
Many risk loci for Parkinson’s disease (PD) have been identified by genome-wide association studies (GWASs), but target genes and mechanisms remain largely unknown. We linked the GWAS-derived chromosome 7 locus (sentinel single-nucleotide polymorphism rs199347) to GPNMB through colocalization analyses of expression quantitative trait locus and PD risk signals, confirmed by allele-specific expression studies in the human brain. In cells, glycoprotein nonmetastatic melanoma protein B (GPNMB) coimmunoprecipitated and colocalized with α-synuclein (aSyn). In induced pluripotent stem cell–derived neurons, loss of GPNMB resulted in loss of ability to internalize aSyn fibrils and develop aSyn pathology. In 731 PD and 59 control biosamples, GPNMB was elevated in PD plasma, associating with disease severity. Thus, GPNMB represents a PD risk gene with potential for biomarker development and therapeutic targeting.

15 August 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ACAlice S. Chen-Plotkin
Alice S. Chen-Plotkin
RARoger Albin
Roger Albin
RARoy Alcalay
Roy Alcalay
DBDebra Babcock
Debra Babcock
VBVikram Bajaj
Vikram Bajaj
JZJing Zhang
Jing Zhang
The recent advent of an “ecosystem” of shared biosample biorepositories and data sets will aid efforts to define biomarkers for Parkinson’s disease.

19 January 2014 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
MGMichael D. Gallagher
Michael D. Gallagher
ESEunran Suh
Eunran Suh
MGMurray Grossman
Murray Grossman
LELauren Elman
Lauren Elman
LMLeo McCluskey
Leo McCluskey
ACAlice S. Chen-Plotkin
Alice S. Chen-Plotkin
Hexanucleotide repeat expansions in chromosome 9 open reading frame 72 (C9orf72) have recently been linked to frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis, and may be the most common genetic cause of both neurodegenerative diseases. Genetic variants at TMEM106B influence risk for the most common neuropathological subtype of FTLD, characterized by inclusions of TAR DNA-binding protein of 43 kDa (FTLD-TDP). Previous reports have shown that TMEM106B is a genetic modifier of FTLD-TDP caused by progranulin (GRN) mutations, with the major (risk) allele of rs1990622 associating with earlier age at onset of disease. Here, we report that rs1990622 genotype affects age at death in a single-site discovery cohort of FTLD patients with C9orf72 expansions (n = 14), with the major allele correlated with later age at death (p = 0.024). We replicate this modifier effect in a 30-site international neuropathological cohort of FTLD-TDP patients with C9orf72 expansions (n = 75), again finding that the major allele associates with later age at death (p = 0.016), as well as later age at onset (p = 0.019). In contrast, TMEM106B genotype does not affect age at onset or death in 241 FTLD-TDP cases negative for GRN mutations or C9orf72 expansions. Thus, TMEM106B is a genetic modifier of FTLD with C9orf72 expansions. Intriguingly, the genotype that confers increased risk for developing FTLD-TDP (major, or T, allele of rs1990622) is associated with later age at onset and death in C9orf72 expansion carriers, providing an example of sign epistasis in human neurodegenerative disease.